Business Context and Reporting Period
This Form 8-K was filed by Aptevo Therapeutics Inc. on February 22, 2017. The report details the Compensation Committee's review of the 2016 Performance Bonus Program and the approval of 2017 base salaries and target bonus percentages for named executive officers.
Key Financial Metrics
The filing does not provide company-wide revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on executive compensation figures:
- 2016 Performance Bonuses Paid:
- Marvin L. White (CEO): $238,880.82
- Jeffrey Lamothe (CFO): $153,472.88
- Scott Stromatt (CMO): $144,900.29
- 2017 Approved Base Salaries:
- Marvin L. White (CEO): $543,387.80
- Jeffrey Lamothe (CFO): $387,407.00
- Scott Stromatt (CMO): $412,563.80
- 2017 Target Bonus Percentages:
- Marvin L. White (CEO): 50% of base salary
- Jeffrey Lamothe (CFO): 40% of base salary
- Scott Stromatt (CMO): 40% of base salary
Material Changes
The filing reports the finalization of 2016 bonus awards based on financial, operational, strategic, and product development milestones. It also establishes the 2017 compensation structure, which includes specific base salary amounts and target bonus percentages for the named executive officers.
Guidance, Outlook, and Risks
Future 2017 bonuses will be contingent upon the achievement of company and individual performance goals as determined by the Compensation Committee. The filing notes that additional compensation details will be included in the proxy statement for the 2017 Annual Meeting of Stockholders. No specific risks or contingencies regarding the company's operations were disclosed in this report.
Investor Verification Checklist
- Verify the specific financial and operational milestones used to calculate the 2016 bonuses.
- Review the upcoming 2017 proxy statement for full details on executive compensation.
- Confirm the impact of these salary and bonus increases on the company's cash burn rate, given the lack of disclosed revenue or profit data in this filing.